The superficial and deep FAZ areas varied significantly among healthy eyes. Factors such as CRT, sex, SE, AL, and choroidal thickness influence the size of the FAZ.

Neovascular age-related macular degeneration (nAMD) is a common world-wide cause of visual loss. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents are an effective means to treat nAMD and reduce its impact on vision compared to either sham treatment or photodynamic therapy. Currently, the approved anti-VEGF drugs include ranibizumab, aflibercept and brolucizumab. In addition, bevacizumab, used as an off-label drug, and has been shown to be effective in treating nAMD. While anti-VEGF agents are effective, its limitations include the requirement for frequent, often monthly injections, and the need for long-term treatment of nAMD. These present significant burdens on the healthcare system and on the patients. In addition, reviews of patients with nAMD treated with anti-VEGF have reported deterioration of vision over time with progression of geographic atrophy. These limitations are partly addressed by exploring different treatment regimens that reduce the frequency of treatments. Newer anti-VEGF drugs have been shown in Phase III clinical trials to have injection intervals as long as 12 or even 16 weeks for a proportion of patients. There is research on newer drugs that affect other pathways, such as the angiopoietin pathway, which may impact nAMD by extending the treatment interval and reducing the burden of treatment. Other measures include the use of sustained-release implants that release the drug regularly over a period of time, and can be refilled periodically, as well as hydrogel platforms that serve to release the drug. The use of biosimilars will also serve to reduce the cost of treatment for nAMD. A new frontier of gene therapy, primarily targeting genes involved in the transduction of retinal cells to produce anti-VEGF proteins intraocularly, also opens a new avenue of therapeutic approaches that can be used for treatment. This review paper will discuss both current treatment options and the newer treatments under development.

No abstract

PURPOSE: To evaluate the use of the Cone Contrast Test (CCT) as a color vision screening tool in an Asian population of aircrew applicants and compare it against the Ishihara Psuedo Isochromatic Plates (PIP) – Edridge Lantern Test (ELT) screening pathway, assessing its impact on attrition with CCT cut-off scores of 55 and 75.METHODS: This is a retrospective review of 862 Republic of Singapore Airforce aircrew applicants tested with CCT and Ishihara PIP–ELT combination as screening. CCT repeatability was analyzed by comparing the subject’s interocular (right vs. left eye) scores measured as the coefficient of repeatability (COR), with COR differing by ≥15 points considered to be outside normal limits.RESULTS: Of the applicants, 17 (1.97%) failed to achieve a CCT score of ≥55 (5 protan, 12 deutan), while 26 (3.02%) applicants failed to achieve a score ≥75 (5 protan, 21 deutan). Of the 17 applicants who obtained a CCT score of <55, 16 failed the Ishihara PIP test. The only applicant who passed the Ishihara PIP test had a CCT score of 50. Of all applicants, 1.7% had a COR of ≥15, with 93.3% of them identified as color vision deficient (CVD). Our results demonstrated excellent test repeatability, with 99.9% (835 out of 836) of color vision normal (CVN) applicants achieving a COR of <15 points.CONCLUSION: Our study demonstrated a high correlation between the CCT (passing score of ≥55) and the Ishihara PIP. Employing the CCT with a passing score of ≥75, instead of the Ishihara PIP–ELT combination, led to an increase in attrition rate of 0.7–3.0%.Chay IW, Lim SWY, Tan BBC. Cone Contrast Test for color vision deficiency screening among a cohort of military aircrew applicants. Aerosp Med Hum Perform. 2019; 90(2):71–76.

No abstract